Experimental tracer maps lung scarring in TB
NCT ID NCT07830771
First seen Sep 21, 2026 · Last updated Sep 21, 2026
Summary
Researchers at the University of Pennsylvania are testing an imaging tracer called [18F]-FAPI-74 to see if it can reveal lung scarring in adults with pulmonary tuberculosis. The study enrolls 10 adults who have cavitary TB and are starting standard treatment. Participants receive a FAP PET/CT scan early in treatment and again after they are cured, along with high-resolution CT scans of the chest. The goal is to learn whether changes in FAP signal track with changes in lung damage, which could help predict who is at risk for lasting lung problems.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- an experimental imaging tracer called [18F]-FAPI-74
- What this could lead to
- If the tracer works, doctors could one day use FAP PET/CT scans to spot lung scarring early and guide treatments that protect lung function after TB is cured.
- What could go wrong
- This is a very small, early-phase imaging study with 10 participants, so it cannot prove that FAP signals predict outcomes. The tracer may not light up lung scarring reliably, and the results may not apply to other TB patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
About 10 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Sep 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
21 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria 1. Participants will be ≥ 21 years of age 2. Diagnosed with microbiologically confirmed (culture or Xpert MTB/RIF PCR positive on at least one respiratory sample) pTB 3. Be currently on or able to initiate standard drug-sensitive pTB treatment according to IDSA guidelines. 4. Have initiated or planning to initiate TB treatment prior to screening and enrollment. 5. Have a Timika CXR score indicating cavitary disease 6. Be able and willing to provide written informed consent to participate in the study Exclusion Criteria 1. Diagnosed with TB that is resistant to rifampin per medical record review or have only extrapulmonary TB. 2. Women of childbearing potential may not be pregnant or breast-feeding. A negative pregnancy test will be required before \[F-18\]-FAPI-74 injection. 3. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician 4. Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study, including completion of the study follow-up or TB treatment. 5. History of major alternative pulmonary disease such as asthma, chronic obstructive pulmonary disease (COPD), or interstitial lung disease as per medical record review or patient self-report. "Major" is defined as potentially resulting in pulmonary radiographic abnormalities that could interfere with interpretation of PET-CT scan data. 6. Have been administered at least 7 days of corticosteroids or any duration of another systemic investigational agent within 3 months of enrollment per medical record review or patient self-report 7. Have symptoms or signs that, in the opinion of the investigative team, are suggestive of active TB at the time of pre-screening per patient self-report
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Tuberculosis, pulmonary are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Perelman School of Medicine, Nuclear Medicine
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a 4-Month drug cocktail cure TB as well as 6 months?
- Can a 4-Drug combo cut TB treatment time in half?
- Can new drug cocktails shorten TB treatment?
- Can higher doses of TB drugs cut treatment time?
- New rapid test could free TB patients from isolation sooner
- New TB cocktail aims to shorten treatment